维普期刊资源整合服务平台（V6.5）

29篇 您的检索式：作者名="Topoi D"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Risk of cardiovascular events associated with selective COX-2 inhibitors 显示文摘	Mukherjee D Nissen SE Topoi EJ	2001	JAMA2001，286，8：	1
2	The restenosis paradigm revisited: an alternative proposal for cellular mechanisms显示文摘	Schwartz R S HOlmes D R Jr Topoi E J	1992	J Am Coll Cardiol1992，20，5：	1
3	The effects of maternal stress and child language ability on behavioral outcomes of children with congenital hearing loss at 18-24 months显示文摘	Topoi D Girard N Pierre LS	2011	Early Human Development2011，87，12：	1
4	Scientific and therapeutic advances in antiplatelet therapy 显示文摘	BHATT D L TOPOI F J	2003	Nat Rcv Drug Discov2003，2，：	1
5	Randomized, double- blind, placebocontrolled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease显示文摘	Topoi EJ Easton D Harrington RA	2003	Circulation2003，108，：	1
6	Risk of cardiovascular events associated with selective COX-2 inhibitors显示文摘	Mukherjee D Nissen SE Topoi EJ	2001	JAMA2001，286，8：	1
7	Scientific and therapeutic advances in antiplatelet therapy 显示文摘	Bhatt D Topoi EJ	2003	Nature Rev2003，2，1：	1
8	The restenosis paradigm revisited: an alternative proposal for cellular mechanisrns显示文摘	Schwartz R S Holmes D R Jr Topoi F J	1992	J Am Coil Cardiol1992，20，5：	1
9	COX-2 : where are we in 2003? Cardiovascular risk and COX-2 inhibitors显示文摘	Mukherjee D Topoi EJ	2003	Arthritis Res Ther2003，5，1：	1
10	Cardiogenic shock complicating acute coronary syndromes显示文摘	Hasdai D Topoi EJ Califf RM	2000	Lancet2000，356，：	1
11	Compari- son of two platelet glycoprotein l] b/]II a inhibitors, tirofi- ban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization显示文摘	Topoi E J Moliterno D J Herrmann HC	2001	N Engl J Med2001，344，25：	1
12	Cardiogenic shock complicating acute coronary syndromes显示文摘	Hasdai D Topoi EJ	2000	The Lancet2000，356，9231：	1
13	Cardiogenic shock complicating acute coronary syndromes 显示文摘	Hasdai D Topoi El Califf RM	2000	Lancet2000，356，9231：	1
14	Comparison of two platelet glycoprotein Ⅱ / Ⅲ a inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization 显示文摘	Topoi E J Moliterno D J Herrmenn H C	2001	N Engl J Med2001，344，25：	1
15	Risk of cardiovascular events associated with selective COX-2inhibitors 显示文摘	Mukherjee D Nissen SE Topoi EJ	2001	JAMA2001，286，：	1
16	Risk of cardiovascular events assoc iated with selective COX-2 inhibitors显示文摘	Mukherjee D Nissen SE Topoi EJ	2002	JAMA2002，286，8：	1
17	Outcome of multivessel coronary intervention in the contemporary percutaneous revascularization era 显示文摘	Shishehbor MH Topoi E J Mukherjee D	2006	Am J Cardiol2006，97，11：	1
18	Three-dimensional integrated circuits 显示文摘	Topoi A W Tulipe D C L Shi L	2006	IBM Journal of Research and Development (S0018-8646)2006，50，45：	1
19	Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy显示文摘	Sane D C Damaraju L V Topoi E J	2000	J Am Coll Cardiol2000，36，1：	1
20	Outcomes at 1 year and economic implication of platelet glycoprotein II b/In a blockade in patients unergoing coronary stenting: results from a multicentre randomised trial显示文摘	Topoi E J Mark D B Lincoff A M	1999	Lancet1999，354，：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示